Generalized Modules for Membrane Antigens (GMMA), an outer membrane vesicle-based vaccine platform, for efficient viral antigen delivery.
immune response
influenza
outer membrane vesicle
rabies
vaccine platform
Journal
Journal of extracellular vesicles
ISSN: 2001-3078
Titre abrégé: J Extracell Vesicles
Pays: United States
ID NLM: 101610479
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
19
04
2022
received:
03
09
2021
accepted:
30
04
2022
entrez:
15
11
2022
pubmed:
16
11
2022
medline:
18
11
2022
Statut:
ppublish
Résumé
Vaccine platforms enable fast development, testing, and manufacture of more affordable vaccines. Here, we evaluated Generalized Modules for Membrane Antigens (GMMA), outer membrane vesicles (OMVs) generated by genetically modified Gram-negative bacteria, as a vaccine platform for viral pathogens. Influenza A virus hemagglutinin (HA), either physically mixed with GMMA (HA+STmGMMA mix), or covalently linked to GMMA surface (HA-STmGMMA conjugate), significantly increased antigen-specific humoral and cellular responses, with HA-STmGMMA conjugate inducing further enhancement than HA+STmGMMA mix. HA-STmGMMA conjugate protected mice from lethal challenge. The versatility for this platform was confirmed by conjugation of rabies glycoprotein (RABVG) onto GMMA through the same method. RABVG+STmGMMA mix and RABVG-STmGMMA conjugate exhibited similar humoral and cellular response patterns and protection efficacy as the HA formulations, indicating relatively consistent responses for different vaccines based on the GMMA platform. Comparing to soluble protein, GMMA was more efficiently taken up in vivo and exhibited a B-cell preferential uptake in the draining lymph nodes (LNs). Together, GMMA enhances immunity against viral antigens, and the platform works well with different antigens while retaining similar immunomodulatory patterns. The findings of our study imply the great potential of GMMA-based vaccine platform also against viral infectious diseases.
Identifiants
pubmed: 36377074
doi: 10.1002/jev2.12247
pmc: PMC9663859
doi:
Substances chimiques
Antigens, Viral
0
glyceryl methyl methacrylate
0
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12247Subventions
Organisme : Department of Health [UK]
Informations de copyright
© 2022 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles.
Références
Vaccines (Basel). 2020 Sep 17;8(3):
pubmed: 32957610
ACS Omega. 2017 Nov 30;2(11):8282-8289
pubmed: 30023580
Vaccine. 2016 Mar 4;34(10):1252-8
pubmed: 26827663
Vaccine. 2019 Oct 8;37(43):6241-6247
pubmed: 31522809
J Gen Virol. 2017 Sep;98(9):2351-2361
pubmed: 28809154
Vaccine. 2015 Apr 21;33(17):2022-9
pubmed: 25776921
ACS Nano. 2020 May 26;14(5):5711-5727
pubmed: 32267667
Front Immunol. 2019 Mar 08;10:335
pubmed: 30906291
Biotechnol Adv. 2017 Sep;35(5):565-574
pubmed: 28522212
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
Vaccine. 2012 Dec 17;31(1):58-83
pubmed: 23142589
Mediators Inflamm. 2018 Sep 06;2018:5697149
pubmed: 30258282
J Gen Virol. 2008 Sep;89(Pt 9):2204-2213
pubmed: 18753230
Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10428-10433
pubmed: 30262653
Vaccine. 2017 Jan 11;35(3):419-426
pubmed: 27998639
J Biol Chem. 2014 Sep 5;289(36):24922-35
pubmed: 25023285
Health Secur. 2020 Jan/Feb;18(1):59-60
pubmed: 32078422
PLoS One. 2015 Aug 06;10(8):e0134478
pubmed: 26248044
Front Immunol. 2020 Mar 04;11:356
pubmed: 32194565
Biotechnol J. 2019 Jul;14(7):1-2
pubmed: 31286673
Adv Drug Deliv Rev. 2017 May 15;114:132-142
pubmed: 28501509
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5
pubmed: 10829079
BioDrugs. 2010 Feb 1;24(1):9-21
pubmed: 20055529
Int J Mol Sci. 2021 Jan 28;22(3):
pubmed: 33525644
Int J Mol Sci. 2020 Jun 21;21(12):
pubmed: 32575921
Front Immunol. 2021 Aug 03;12:715393
pubmed: 34413858
J Virol Methods. 2011 Feb;171(2):369-73
pubmed: 21146560
Cytokine Growth Factor Rev. 2010 Dec;21(6):443-8
pubmed: 21095154
Vaccines (Basel). 2022 Feb 04;10(2):
pubmed: 35214700
Front Immunol. 2017 Dec 22;8:1884
pubmed: 29375556
Vaccine. 2019 Dec 3;37(51):7501-7508
pubmed: 31564450
Nat Rev Immunol. 2013 Jul;13(7):475-86
pubmed: 23797063
J Appl Oral Sci. 2014 Jul-Aug;22(4):336-46
pubmed: 25141207
Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15194-15199
pubmed: 31296560
Nat Commun. 2020 Jul 9;11(1):3523
pubmed: 32647131
Curr Opin Immunol. 2017 Apr;45:97-102
pubmed: 28319733
Nat Commun. 2021 Apr 6;12(1):2041
pubmed: 33824314
Clin Vaccine Immunol. 2016 Apr 04;23(4):304-14
pubmed: 26865597
Front Microbiol. 2021 Feb 04;12:629090
pubmed: 33613498
Front Immunol. 2021 Dec 17;12:781280
pubmed: 34987509
Nat Med. 2004 Nov;10(11):1177-85
pubmed: 15516917
J Extracell Vesicles. 2013 May 06;2:
pubmed: 24009891
Front Microbiol. 2018 Apr 26;9:783
pubmed: 29755431
J Extracell Vesicles. 2022 Nov;11(11):e12247
pubmed: 36377074
Glycobiology. 2017 Jan;27(1):3-49
pubmed: 27558841
Nat Rev Immunol. 2015 Jun;15(6):375-87
pubmed: 25976515
Biotechnol J. 2015 Sep;10(11):1689-706
pubmed: 26912077